Business Description

Novo Nordisk A/S, a global healthcare company, focusing on developing, manufacturing, marketing, and discovering pharmaceutical products, is Novo Nordisk A/S. The company was founded in 1923 by Harald Pedersen, and Thorvald Pedersen. It is headquartered at Bagsvaerd in Denmark. Its products are sold in more than 168 countries. The company’s business is conducted through the Biopharm and Diabetes and Obesity Care segments. Biopharm focuses on rare blood disorders, rare endocrine conditions, and hormone replacement therapy. It has 10 research and development centers in 5 countries and 16 production facilities in 9 countries.

Key Financials

Revenue (US$ Mn)

• Novo Nordisk A/S’s annual revenue for 2021 was US$ 21,440 Mn, a 25.67% increase from 2020
• The annual revenue generated by Novo Nordisk A/S in 2020 was US$ 17,061 Mn
• At an 8.98% increase, Novo Nordisk A/S’s annual revenue of US$ 16,334 Mn was indexed in 2019
• Novo Nordisk A/S generated total revenue of US$ 14,988 Mn in 2018

Operating Income(US$ Mn)

• US$ 8,930 Mn was Novo Nordisk A/S’s operating income in 2021, a 22.76% increase from 2020 figures
• Novo Nordisk A/S indexed a 3.54% increase in operating incomes from 2019, amounting to US$ 7,274 Mn in 2020
• Novo Nordisk A/S generated an operating income of US$ 7,025 Mn in 2019
• An operating income of US$ 6,332 Mn was indexed by Novo Nordisk A/S in 2018

Net Income(US$ Mn)

• US$ 7,272 Mn was the net income generated by Novo Nordisk A/S in 2021
• Novo Nordisk A/S’s net income for 2020 was US$ 5,663 Mn, an 8.61% increase from 2019
• From 2018’s net incomes, Novo Nordisk A/S registered a 0.71% increase in 2019, amounting to US$ 5,214 Mn
• A net income of US$ 5,177 Mn was generated in 2018 by Novo Nordisk A/S

Operating Margin %

• Novo Nordisk A/S’s operating margin for 2021 was 42%, a -2.11% decrease from 2020
• The operating margin generated by Novo Nordisk A/S in 2020 was 43%
• At a 1.9% increase, Novo Nordisk A/S’s operating margin of 43% was indexed in 2019
• Novo Nordisk A/S generated an operating margin of 42% in 2018

Gross Margin %

• 83% was Novo Nordisk A/S’s gross margin in 2021, a -0.36% decrease from 2020 figures
• Novo Nordisk A/S indexed a 0% decrease in gross margins from 2019, amounting to 84% in 2020
• Novo Nordisk A/S generated a gross margin of 84% in 2019
• A gross margin of 84% was indexed by Novo Nordisk A/S in 2018

SWOT Analysis

Strengths

Strong research and development activities provide a competitive advantage

Novo Nordisk is involved in extensive R&D to develop medicines for chronic and non-chronic conditions. The company’s main therapy areas include type 1 and 2 diabetes, obesity and Non-alcoholic Steatohepatitis, Haemophilia, Growth Disorders, Haemophilia, and Atherosclerosis. The company had 13 R&D centers and transformational research units across Europe, America, China, India, and China as of December 31, 2020. The company spent DKK15.462 million on R&D in FY2020. This was 12.2 %.

Get this premium content

The Premium data is Locked

Buy Now to Unlock Premium Data

Request Sample Data